Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Celltrion

Biotech & Life Sciences · Incheon, South Korea · Founded 2002 · IPO 2005 Decacorn

Global biotech company that launched the world's first monoclonal antibody biosimilar

Valuation
$39B
Market cap · May/2026
Revenue
$3.45B
Latest reported FY
EBITDA
$1.29B
Latest reported FY

Investors

2 investors on Celltrion's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
KT&G Corporation
VaxGen

Global footprint

Where Celltrion has talent and traffic

Workforce by country
🇰🇷 South Korea · Incheon HQ
Book a demo for the full country breakdown
Web traffic by country
120K monthly visits
across markets
🏳️ Korea83.3%
🏳️ Republic of5.4%
🇮🇳 India3.4%
🇺🇸 United States1.7%
🇨🇦 Canada1.6%
Top 5 markets shown

Patent intelligence

$101M patent portfolio · 149 active families

Estimated portfolio value
$101M
0.26% of market cap · 2.3× smaller than top peer Galapagos ($230M)
149 active patent families
Where Celltrion innovates Pharmaceutical drugDrugMedicinal chemistryChemical formulaPharmaceutical Substances

Where Celltrion concentrates vs peers

Each axis is a top-10 topic across Celltrion and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Celltrion's 4 investments and acquisitions.

Every disclosed deal where Celltrion appeared as a backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Celltrion's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Celltrion deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Celltrion's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Celltrion

        An AI-synthesized read of the highest-engagement posts about Celltrion on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Celltrion on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.